This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Astrazeneca Ab. Active years: 2012.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2012
Title: The Innovations of Andrew John Day
Introduction
Andrew John Day is a notable inventor based in Macclesfield, GB. He has made significant contributions to the field of pharmaceuticals, particularly with his innovative compositions. His work is recognized for its potential impact on medical treatments.
Latest Patents
Andrew John Day holds a patent for a pharmaceutical composition titled "Composition 064." This composition comprises N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide combined with mannitol and/or 5 microcrystalline cellulose. This invention showcases his expertise in developing effective pharmaceutical solutions.
Career Highlights
Andrew is associated with AstraZeneca AB, a leading global biopharmaceutical company. His role at AstraZeneca has allowed him to work on groundbreaking research and development projects. His contributions have been instrumental in advancing pharmaceutical innovations.
Collaborations
Throughout his career, Andrew has collaborated with talented individuals such as John David Blyth and Kieran James Lennon. These partnerships have fostered a creative environment that encourages the development of new ideas and solutions.
Conclusion
Andrew John Day's work exemplifies the spirit of innovation in the pharmaceutical industry. His patent and collaborations highlight his commitment to advancing medical science. His contributions are likely to have a lasting impact on healthcare solutions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile